Á¦49Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦9Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º 2 : 2023-06-16
±³À°ÀÏÀÚ : 2023-06-16
±³À°Àå¼Ò : ¼¿ï·Ôµ¥È£ÅÚ 2,3Ãþ
±³À°ÁÖÁ¦ : Á¦49Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦9Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º 2
ÁÖÃÖ±â°ü : ´ëÇѾÏÇÐȸ
´ã´çÀÚ : ÀÌÈñ¿¬
¿¬¶ôó : 02-792-1486
À̸ÞÀÏ : cancer2@kams.or.kr
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, ¼ºÇü¿Ü°ú, ¾È°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, ºñ´¢ÀÇÇаú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаú, ¿¹¹æÀÇÇÐ, ÇغÎÇÐ, »ý¸®ÇÐ, »ýÈÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀÎ : 1500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 19 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 200,000¿ø
ºñ°í "1. ȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 10¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 5¸¸¿ø / 3) ¾÷ü ¹× ¿¬±¸¼Ò: 15¸¸¿ø
2. ºñȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 15¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 7¸¸¿ø / 3) ¾÷ü ¹× ¿¬±¸¼Ò: 20¸¸¿ø"
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal A 09:00~09:20 Nationwide network of genomic medicine Juergen Wolf(University Hospital Cologne, Germany)
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal A 09:20~09:40 Leveraging genomic data into clinic, -or even clinical trials ¾È¼º±Í(°³²¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal A 09:40~10:00 Prescribing genomic analyses in clinic, evidences and practical issues ±è½ÃÇö(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal B 09:00~09:30 A mechanism of oncogene amplification in breast cancer June-Koo Lee(Memorial Sloan Kettering Cancer Center, USA)
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal B 09:30~09:50 Cancer prevention È«Á¤¿ë(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal B 09:50~10:10 Unraveling the role of neural stem cells in glioblastoma and targeting tumor-initiating cells to prevent recurrence ÀÌÁÖÈ£(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 16ÀÏ Sapphire A 09:00~09:20 Molecular pathology of pediatric brain tumors ±è¼¼ÈÆ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06¿ù 16ÀÏ Sapphire A 09:20~09:40 Molecular targeted therapy for pediatric brain tumors ÃÖÁ¤À±(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 16ÀÏ Sapphire A 09:40~10:00 Personalized medicine in brain tumors ³²µµÇö(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06¿ù 16ÀÏ Sapphire B 09:30~10:00 Next-generation approaches to discovering therapeutics and therapeutic targets in cancer William R. Sellers(Broad Institute, USA)
ÈÞ½Ä 06¿ù 16ÀÏ 10:00~10:20 ÈÞ½Ä ()
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal A 10:20~11:00 Adjuvant treatment of resectable gastric cancer. Where are we now in Asia? °À±±¸(¿ï»êÀÇ´ë)
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal A 11:00~11:40 Mechanism of action and inflammatory axis for air pollution induced non-small cell lung cancer Charles Swanton(Francis Crick Institute & UCL Cancer Institute, UK)
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal A 11:40~12:20 New approaches for treatment of small cell lung cancer ¾Èº´Ã¶(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal B 11:40~12:00 IO in GC/GEJ/EAC 1L with 3y long-term data ¹è¿ì±Õ(Àü³²ÀÇ´ë)
±³À°½Ã°£ 06¿ù 16ÀÏ Sapphire A 11:40~12:00 Take hope further for HR+HER2- high-risk early breast cancer patients with abemiciclib À̱ټ®(±¹¸³¾Ï¼¾ÅÍ)
½Ä»ç 06¿ù 16ÀÏ 12:20~13:20 ½Ä»ç ()
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal A 13:20~13:45 Genomic approaches to identifying neoantigen vaccine and CAR therapy targets ÃÖÁ¤±Õ(KAIST)
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal A 13:45~14:10 Implications of cancer cell state plasticity for therapeutic intervention Wai Leong Tam(CSI Singapore & National University of Singapore, Singapore)
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal A 14:10~14:35 R-loop-induced phase separation instigates the Alternative Lengthening of Telomeres (ALT) upon BRCA2 abrogation ÀÌÇö¼÷(¼¿ï´ë)
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal A 14:35~15:00 Widespread upregulation of 3¡¯UTR splicing in cancers Yvonne Tay(CSI Singapore, National University of Singapore, Singapore)
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal B 13:20~13:45 Glioblastoma metabolism and radioresistance À±ºÎÇö(ºÎ»ê´ë)
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal B 13:45~14:10 Ceria-based nanoparticles for therapeutic antioxidants and radioprotectants ÇöÅÃȯ(¼¿ï´ë)
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal B 14:10~14:35 Immune-regulatory radiosensitizers ±èÀ缺(Çѱ¹¿øÀÚ·ÂÀÇÇпø)
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal B 14:35~15:00 Novel radiosensitizers Chunlin Shao(Fudan University, China)
±³À°½Ã°£ 06¿ù 16ÀÏ Sapphire A 13:20~13:45 Changes in the tumor immune microenvironment during treatment in ovarian cancer ÀÌÁ¤À±(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06¿ù 16ÀÏ Sapphire A 13:45~14:10 Immunotherapy related biomarker in gynecologic cancer È«¼÷Èñ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 06¿ù 16ÀÏ Sapphire A 14:10~14:35 Brachytherapy in cervical cancer ±è¿¬ÁÖ(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 06¿ù 16ÀÏ Sapphire A 14:35~15:00 Recent update of the radiologic characterization and report of ovarian cancer Ȳ¼ºÀÏ(ºÐ´ç¼¿ï´ëº´¿ø)
±³À°½Ã°£ 06¿ù 16ÀÏ Sapphire B 13:20~13:45 NOIU ±¹³» Ç×¾Ï½Å¾à °³¹ß Á߿伺 ¹× Àü¸Á ±èÇбÕ(Ç׾Ͻžà½ÅÄ¡·á°³¹ß»ç¾÷´Ü)
±³À°½Ã°£ 06¿ù 16ÀÏ Sapphire B 13:45~14:10 Next generation PARP and TNKS inhibitor development ±èÁ¸(Onconic)
±³À°½Ã°£ 06¿ù 16ÀÏ Sapphire B 14:10~14:35 HPV therapeutic vaccine development for the treatment of recurrent/metastatic cervical cancer ¹ÚÁ¾¼·(Genexine)
±³À°½Ã°£ 06¿ù 16ÀÏ Sapphire B 14:35~15:00 T cell agonist anti-4-BB in the clinical trial ÀÌÁß¿ø(Eutilex)
ÈÞ½Ä 06¿ù 16ÀÏ 15:00~15:20 ÈÞ½Ä ()
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal A 15:20~15:45 Design and interpretation of (Neo)adjuvant trials Á¶ÁÖÈñ(¼º±Õ°ü´ë)
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal A 15:45~16:10 Pathologic assessments after neoadjuvant treatments °ø°æ¿±(¿ï»êÀÇ´ë)
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal A 16:10~16:35 Pathologic complete response as an endpoint in clinical trials ±èÁöÇö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal A 16:35~17:00 Neoadjuvant vs. adjuvant chemoimmunotherapy °ÀºÁÖ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal B 15:20~15:45 Analyzing method for spatial biology Quan Nguyen(The University of Queensland, Australia)
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal B 15:45~16:10 New method for data genration of spatial biology (proteomics/multiomics) ±Ç¼ºÈÆ(¼¿ï´ë)
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal B 16:10~16:35 Immune checkpoint inhibitors in gastric cancer Tae Hyun Hwang(Mayo Clinic, USA)
±³À°½Ã°£ 06¿ù 16ÀÏ Crystal B 16:35~17:00 Spatial transcriptomics for clinical translation ³ª±ÇÁß(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06¿ù 16ÀÏ Sapphire A 15:20~15:45 MDT management of HCC Dandan Hu(Sun Yat-Sen University Cancer Center, China)
±³À°½Ã°£ 06¿ù 16ÀÏ Sapphire A 15:45~16:10 Recent progress for early detection of HCC in chronic liver diseases ¼ºÇʼö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 06¿ù 16ÀÏ Sapphire A 16:10~16:35 Emerging neoadjuvant or conversion therapies Tianqiang Song(Tianjin Medical University Cancer Institute & Hospital, China)
±³À°½Ã°£ 06¿ù 16ÀÏ Sapphire A 16:35~17:00 Could we predict the response of immune checkpoint inhibitor treatment in hepatocellular carcinoma? ÀüÈ«Àç(Â÷ÀÇ´ë)
±³À°½Ã°£ 06¿ù 16ÀÏ Sapphire B 15:20~15:45 ¾ÏÁ¤¹ÐÀÇÇп¡¼ NGS ÀÓ»ó Àû¿ëÀÇ ±Û·Î¹ú ÇöȲ À±½Å±³(¿ï»êÀÇ´ë)
±³À°½Ã°£ 06¿ù 16ÀÏ Sapphire B 15:45~16:10 ¾Ï Áø´Ü ¹× Ä¡·á °úÁ¤¿¡¼ À¯Àüü ÇÁ·ÎÆÄÀϸµÀÇ ¿ªÇÒ ¹× ¹Ì·¡ (ÀǾà¾÷°è Àü¸Á) ±è½ÂÀº(³ë¹ÙƼ½º)
±³À°½Ã°£ 06¿ù 16ÀÏ Sapphire B 16:10~16:35 ±¹³» NGS ±â¹Ý ¾ÏÁ¤¹ÐÀÇ·á ¿¬±¸ Ç÷§Æû - KOSMOS II ±è¼±¿µ(¼¿ï¾Æ»êº´¿ø)
Åä·Ð 06¿ù 16ÀÏ Sapphire B 16:35~17:00 Q&A Discussion ()